Equillium, Inc.

Healthcare · Biotechnology · United States

Last price 1.42 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 111.28M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its n...